PT1856090E - Derivados de tiofeno substituído como antagonistas do receptor de glucagona, preparação e usos terapêuticos - Google Patents

Derivados de tiofeno substituído como antagonistas do receptor de glucagona, preparação e usos terapêuticos Download PDF

Info

Publication number
PT1856090E
PT1856090E PT06720513T PT06720513T PT1856090E PT 1856090 E PT1856090 E PT 1856090E PT 06720513 T PT06720513 T PT 06720513T PT 06720513 T PT06720513 T PT 06720513T PT 1856090 E PT1856090 E PT 1856090E
Authority
PT
Portugal
Prior art keywords
glucagon receptor
preparation
compounds
receptor antagonists
therapeutic uses
Prior art date
Application number
PT06720513T
Other languages
English (en)
Portuguese (pt)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1856090(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT1856090E publication Critical patent/PT1856090E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT06720513T 2005-02-11 2006-02-09 Derivados de tiofeno substituído como antagonistas do receptor de glucagona, preparação e usos terapêuticos PT1856090E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11

Publications (1)

Publication Number Publication Date
PT1856090E true PT1856090E (pt) 2009-11-18

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06720513T PT1856090E (pt) 2005-02-11 2006-02-09 Derivados de tiofeno substituído como antagonistas do receptor de glucagona, preparação e usos terapêuticos

Country Status (25)

Country Link
US (1) US8084489B2 (OSRAM)
EP (1) EP1856090B1 (OSRAM)
JP (1) JP4988604B2 (OSRAM)
KR (1) KR20070104409A (OSRAM)
CN (1) CN101115735B (OSRAM)
AT (1) ATE445609T1 (OSRAM)
AU (1) AU2006213894B2 (OSRAM)
BR (1) BRPI0607015A2 (OSRAM)
CA (1) CA2597073C (OSRAM)
CR (1) CR9304A (OSRAM)
CY (1) CY1109624T1 (OSRAM)
DE (1) DE602006009773D1 (OSRAM)
DK (1) DK1856090T3 (OSRAM)
EA (1) EA200701705A1 (OSRAM)
ES (1) ES2332470T3 (OSRAM)
IL (1) IL184932A0 (OSRAM)
MA (1) MA29432B1 (OSRAM)
MX (1) MX2007009661A (OSRAM)
NO (1) NO20074567L (OSRAM)
PL (1) PL1856090T3 (OSRAM)
PT (1) PT1856090E (OSRAM)
SI (1) SI1856090T1 (OSRAM)
TN (1) TNSN07313A1 (OSRAM)
WO (1) WO2006086488A2 (OSRAM)
ZA (1) ZA200706354B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51202B (sr) * 2004-06-14 2010-12-31 Eli Lilly And Company Antagonisti receptora za glukagon, dobijanje i terapeutske upotrebe
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
KR101638671B1 (ko) 2011-02-08 2016-07-11 화이자 인코포레이티드 글루카곤 수용체 조절자
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES
US20180289859A1 (en) 2015-10-05 2018-10-11 Hettwer Holding Aps Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
CN118236497A (zh) 2016-08-30 2024-06-25 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists
EP4285723A3 (en) 2019-12-20 2024-03-27 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511683A (ja) * 2001-12-03 2005-04-28 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
EP1519723A1 (en) * 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
EP1758859B1 (en) * 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
RS51202B (sr) * 2004-06-14 2010-12-31 Eli Lilly And Company Antagonisti receptora za glukagon, dobijanje i terapeutske upotrebe

Also Published As

Publication number Publication date
MA29432B1 (fr) 2008-05-02
CN101115735A (zh) 2008-01-30
AU2006213894B2 (en) 2011-12-08
JP4988604B2 (ja) 2012-08-01
EP1856090B1 (en) 2009-10-14
SI1856090T1 (sl) 2010-02-26
TNSN07313A1 (en) 2008-12-31
ATE445609T1 (de) 2009-10-15
KR20070104409A (ko) 2007-10-25
AU2006213894A1 (en) 2006-08-17
NO20074567L (no) 2007-11-08
CR9304A (es) 2008-03-31
WO2006086488A2 (en) 2006-08-17
DE602006009773D1 (de) 2009-11-26
CA2597073C (en) 2014-11-25
CA2597073A1 (en) 2006-08-17
EA200701705A1 (ru) 2008-02-28
US8084489B2 (en) 2011-12-27
MX2007009661A (es) 2007-09-25
ZA200706354B (en) 2008-11-26
US20100137417A1 (en) 2010-06-03
DK1856090T3 (da) 2009-11-30
JP2008530102A (ja) 2008-08-07
CN101115735B (zh) 2013-01-09
ES2332470T3 (es) 2010-02-05
BRPI0607015A2 (pt) 2009-12-01
CY1109624T1 (el) 2014-08-13
PL1856090T3 (pl) 2010-02-26
EP1856090A2 (en) 2007-11-21
WO2006086488A3 (en) 2006-12-14
IL184932A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
PL1861360T3 (pl) Pochodne pirolidyny jako antagoniści receptora histaminowego H3